Research
RSM01, an extended half-life RSV monoclonal antibody with a high barrier to in vitro resistance
Nature ·
The Brief
- Nature publishes a research article on RSM01, an RSV monoclonal antibody with an extended half-life.
- The source reports the antibody has a high barrier to in vitro resistance.
- The feed entry provides no summary, so further technical details are not available from the sources.
Why it matters
An antibody with a longer half-life could mean less frequent dosing for protecting infants and adults against respiratory syncytial virus, though the sources only confirm the headline claims.
Who’s affected
- clinicians and researchers working on RSV prevention
- infectious disease scientists
- #rsv
- #monoclonal antibody
- #antiviral resistance
- #immunology